progenipoietin

Progenipoietin is a recombinant chimeric protein that combines portions of the ligands for granulocyte colony-stimulating factor (G-CSF) and human fetal liver tyrosine kinase-3 (FLT3). It acts as an agonist at both the G-CSF receptor and FLT3 receptor. This dual-receptor activity stimulates hematopoiesis by promoting proliferation and mobilization of hematopoietic stem cells and dendritic cells. Preclinical studies have shown that progenipoietin can enhance expansion of dendritic cells with anti-tumor properties and more effectively mobilize transplantable hematopoietic stem cells than either G-CSF or FLT3 ligand alone. Developed originally by Searle (later Pharmacia), it was investigated primarily for use in cancer-related myelosuppression but development was discontinued[1][2][5][7][8].

Other names

progenipoietin